Cargando…

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection

In the present study, immunogenicity data in 61 vaccinated healthcare workers (HCWs) either infection naïve (naïve HCWs) or with infection of Delta and/or Omicron COVID-19 (experienced HCWs) were evaluated up to 270 days after the second dose of BNT162b2 vaccine and up to 90 days after a booster dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vietri, Maria Teresa, D'Elia, Giovanna, Caliendo, Gemma, Passariello, Luana, Albanese, Luisa, Molinari, Anna Maria, Angelillo, Italo Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411148/ https://www.ncbi.nlm.nih.gov/pubmed/36041940 http://dx.doi.org/10.1016/j.vaccine.2022.08.045

Ejemplares similares

Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease
por: Albanese, Luisa, et al.
Publicado: (2022)

Hereditary Cancer Syndrome in a Family with Double Mutation in BRIP1 and MUTYH Genes
por: D’Elia, Giovanna, et al.
Publicado: (2023)

Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in BRCA and in Other Susceptibility Genes
por: D’Elia, Giovanna, et al.
Publicado: (2022)

Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention
por: Vietri, Maria Teresa, et al.
Publicado: (2021)

Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer
por: Vietri, Maria Teresa, et al.
Publicado: (2021)

APC and MUTYH Analysis in FAP Patients: A Novel Mutation in APC Gene and Genotype-Phenotype Correlation
por: D’Elia, Giovanna, et al.
Publicado: (2018)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
por: Naaber, Paul, et al.
Publicado: (2022)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort
por: Mauro, Daniele, et al.
Publicado: (2022)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2022)

Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
por: Amir, Ofra, et al.
Publicado: (2023)

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
por: Favresse, Julien, et al.
Publicado: (2022)

Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil
por: Florentino, Pilar T V, et al.
Publicado: (2022)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Five Italian Families with Two Mutations in BRCA Genes
por: Vietri, Maria Teresa, et al.
Publicado: (2020)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
por: Campos, Guilherme R. F., et al.
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant
por: Campos, Guilherme R. F., et al.
Publicado: (2022)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster
por: Wagenhäuser, Isabell, et al.
Publicado: (2023)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
por: Pérez-Then, Eddy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_du3gdqfk3pa49kold2log7unfq